|
US2010160428A1
|
|
Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits
|
|
WO2006115421A1
|
|
Copper regulation evaluation and therapy
|
|
WO2006104399A1
|
|
Copper antagonist compositions
|
|
WO2006104401A1
|
|
Copper antagonist compositions
|
|
WO2006104398A1
|
|
Copper antagonist compositions
|
|
WO2006104397A1
|
|
Copper antagonist compositions
|
|
WO2006104396A1
|
|
Pre-complexed copper antagonist compositions
|
|
WO2006104400A1
|
|
Copper antagonist compositions
|
|
WO2006104402A1
|
|
Copper antagonist compositions
|
|
EP1830873A1
|
|
Glyponectin (glycosylated adiponectin) for the treatment of diseases and conditions
|
|
CA2577634A1
|
|
Synthesis of triethylenetetramines
|
|
CA2550505A1
|
|
Copper antagonist compounds
|
|
CN1898260A
|
|
Peptides with anti-obesity activity and other related uses
|
|
CN1688301A
|
|
Dosage forms and related therapies
|
|
CN1684705A
|
|
Methods of use of compounds with preptin function
|
|
WO03093311A1
|
|
Proteins with deglycating activities and methods of using same
|
|
NZ545724A
|
|
Use of a copper chelator for preventing and/or treating cardiovascular disease and/or associated heart failure
|
|
AU2003214725A1
|
|
Preventing and/or treating cardiovascular disease and/or associated heart failure
|
|
AU2003222513A1
|
|
Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
|
|
CN1649897A
|
|
FALP proteins
|
